Information for Doctors

RABBIT at a glance

GoalsLong-term monitoring of safety and efficacy of therapy with biologics, biosimilars and JAK inhibitors in patients with rheumatoid arthritis (RA) compared to therapy with conventional, synthetic DMARDs
Study designProspective observational study
Participating physiciansRheumatologists in practice or special outpatient departments throughout Germany. The participation of new facilities is possible at any time! Please register via the contact form
Inclusion criteriaPatients with confirmed RA diagnosis by the rheumatologist stating the ACR criteria of 1987,
disability age >=16 years,
start of a new therapy with a biologic, biosimilar or JAK inhibitor or
restart of a therapy with a biologic, biosimilar or JAK inhibitor - without exception - after at least a three-month therapy break or
start of a therapy with a conventional DMARD after failure of at least a conventional DMARD therapy.

Here we provide a list of all currently approved therapies.

Data collectionQuestionnaires for physician and patient at the time of inclusion (at the beginning of the new therapy), after 3 and 6 months and at 6-month intervals thereafter
Observation timeAt least 5 years
Time required for the physicianFor the base bow approx. 15-30 minutes per patient,
for a follow-up sheet about 10 to 15 minutes per patient
Study managementPharmacoepidemiology working group of the German Rheumatism Research Center in Berlin